<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3775">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057769</url>
  </required_header>
  <id_info>
    <org_study_id>KY20162097-1</org_study_id>
    <nct_id>NCT03057769</nct_id>
  </id_info>
  <brief_title>Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin</brief_title>
  <official_title>Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin: A Multi-center, Double-blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to
      30% of procedures. It accounts for substantial morbidity and represents a substantial cost
      to health-care systems. European Society of Gastrointestinal Endoscopy and Japanese Society
      of Hepato-Biliary-Pancreatic surgery guidelines and recently large-scale RCT recommended
      routine use of NSAIDs indomethacin rectally before ERCP. Nonsteroidal anti-inflammatory
      drugs (NSAIDs) have been shown to inhibit prostaglandin synthesis, phospholipase A2
      activity, and neutrophil/endothelial cell attachment, which is believed to play a key role
      in the pathogenesis of acute pancreatitis.

      Other possible mechanisms have been suggested in the occurrence of pancreatitis. Papillary
      edema caused by manipulations during cannulation or endoscopic treatment has received the
      most attention. The papillary edema may cause temporary outflow obstruction of pancreatic
      juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis.
      Topical application of epinephrine on the papilla may reduce papillary edema by decreasing
      capillary permeability or by relaxing the sphincter of Oddi. A meta-analysis (including 2
      existing RCTs and post-hoc analysis of our previous study) of papillary epinephrine spraying
      compared with saline spraying or no intervention indicates a potential relative risk
      reduction of PEP (RR 0.34, 95%CI 0.19-0.61). Papillary epinephrine spraying may be an
      inexpensive and convenient alternative for prevention of post-ERCP pancreatitis. A large
      pragmatic RCT to determine whether routine using papillary epinephrine spraying can reduce
      post-ERCP pancreatitis is needed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall post-ERCP pancreatitis (PEP)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moderate to severe PEP</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical significant gastrointestinal bleeding</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall ERCP complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity of PEP evaluated by updated Atlanta criteria</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ERCP-related perforation</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Biliary infection</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of post-procedure hospital stay</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Pancreatitis</condition>
  <condition>Endoscopic Retrograde Cholangiopancreatography</condition>
  <arm_group>
    <arm_group_label>PES group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Papillary epinephrine spraying</intervention_name>
    <description>All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.</description>
    <arm_group_label>PES group</arm_group_label>
    <other_name>PES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Papillary saline spraying</intervention_name>
    <description>All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.</description>
    <arm_group_label>PES group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old patients planned for ERCP.

        Exclusion Criteria:

          -  contraindications to ERCP

          -  allergy to epinephrine or NSAIDs

          -  Not suitable for pre-ERCP indomethacin (received NSAIDs within 7 days before the
             procedure; gastrointestinal hemorrhage within 4 weeks; renal dysfunction [Cr
             &gt;1.4mg/dl=120umol/l]; presence of coagulopathy before the procedure)

          -  previous biliary sphincterotomy without planned pancreatic duct manipulation

          -  ERCP for biliary stent removal or exchange without planned pancreatic duct
             manipulation

          -  acute pancreatitis within 3 days before the procedure

          -  unwilling or inability to provide consent

          -  pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanglin Pan, M.D.</last_name>
    <email>yanglinpan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Hui, M.D.</last_name>
    <email>fmmulh@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology, Successful Hospital of Xiamen university</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yichen Dai</last_name>
      <phone>+8613600901827</phone>
      <email>dyichen@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Zeng</last_name>
      <phone>+8618605026351</phone>
      <email>weizeng2166@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yuanyuan Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaosan Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rongqing Gong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Zhongshan Hospital of Xiamen university</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijuan Si</last_name>
      <phone>+8613950102330</phone>
      <email>silijuan1981@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoqing Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenming Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yunpeng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of General Surgery, The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xun Li</last_name>
      <phone>+8613993138612</phone>
      <email>lxdr21@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Ping Yue</last_name>
      <phone>+8615095354426</phone>
      <email>dryueping@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhenzhen Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoscopy Center, Ankang Central Hospital</name>
      <address>
        <city>Ankang</city>
        <state>Shaanxi</state>
        <zip>725000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaocui Yang</last_name>
      <phone>+8615909155016</phone>
      <email>akyxc@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongfeng He</last_name>
      <phone>+8615891456777</phone>
      <email>yfenghe@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qiang Zou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenwei Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanglin Pan, M.D.</last_name>
      <phone>862984771536</phone>
      <email>yanglinpan@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hui Luo, M.D.</last_name>
      <phone>862984771536</phone>
      <email>fmmulh@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qin Tao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, No. 451 Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhou</last_name>
      <phone>+8613399289251</phone>
      <email>zhouyi02192005@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Mei Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suli Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, The First Affiliated Hospital of the Medical College, Shihezi University</name>
      <address>
        <city>Shihezi</city>
        <state>Xinjiang</state>
        <zip>832008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Chen</last_name>
      <phone>+8613579456959</phone>
      <email>cwg_sh@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanzhi Han</last_name>
      <phone>+8615001638885</phone>
      <email>296900105@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guochen Shang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Urumqi General Hospital of Lanzhou Military Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanguo Nie</last_name>
      <phone>+8613999116558</phone>
      <email>niezg@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Lei</last_name>
      <phone>+8618999838871</phone>
      <email>lting.xj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jinshan Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng Zhang</last_name>
      <phone>+8613758250208</phone>
      <email>zxf837@tom.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Yang</last_name>
      <email>yang98118@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qifeng Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kangwei Xiong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University</name>
      <address>
        <city>Ningxia</city>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Wang, M.D.</last_name>
      <phone>+8613895098592</phone>
      <email>wq-6562@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Feng Wang, M.D.</last_name>
      <phone>+8613995183326</phone>
      <email>wf4065335@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianjun Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004 Jun;59(7):845-64. Review.</citation>
    <PMID>15173799</PMID>
  </reference>
  <reference>
    <citation>Dumonceau JM, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C; European Society of Gastrointestinal Endoscopy.. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy. 2014 Sep;46(9):799-815. doi: 10.1055/s-0034-1377875.</citation>
    <PMID>25148137</PMID>
  </reference>
  <reference>
    <citation>Yokoe M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, Itoi T, Sata N, Gabata T, Igarashi H, Kataoka K, Hirota M, Kadoya M, Kitamura N, Kimura Y, Kiriyama S, Shirai K, Hattori T, Takeda K, Takeyama Y, Hirota M, Sekimoto M, Shikata S, Arata S, Hirata K. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci. 2015 Jun;22(6):405-32. doi: 10.1002/jhbp.259. Epub 2015 May 13. Review.</citation>
    <PMID>25973947</PMID>
  </reference>
  <reference>
    <citation>Luo H, Zhao L, Leung J, Zhang R, Liu Z, Wang X, Wang B, Nie Z, Lei T, Li X, Zhou W, Zhang L, Wang Q, Li M, Zhou Y, Liu Q, Sun H, Wang Z, Liang S, Guo X, Tao Q, Wu K, Pan Y, Guo X, Fan D. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. Lancet. 2016 Jun 4;387(10035):2293-301. doi: 10.1016/S0140-6736(16)30310-5. Epub 2016 Apr 28.</citation>
    <PMID>27133971</PMID>
  </reference>
  <reference>
    <citation>Ding X, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc. 2012 Dec;76(6):1152-9. doi: 10.1016/j.gie.2012.08.021.</citation>
    <PMID>23164513</PMID>
  </reference>
  <reference>
    <citation>Matsushita M, Takakuwa H, Shimeno N, Uchida K, Nishio A, Okazaki K. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol. 2009;44(1):71-5. doi: 10.1007/s00535-008-2272-8. Epub 2009 Jan 22.</citation>
    <PMID>19159075</PMID>
  </reference>
  <reference>
    <citation>Tarnasky P, Cunningham J, Cotton P, Hoffman B, Palesch Y, Freeman J, Curry N, Hawes R. Pancreatic sphincter hypertension increases the risk of post-ERCP pancreatitis. Endoscopy. 1997 May;29(4):252-7.</citation>
    <PMID>9255527</PMID>
  </reference>
  <reference>
    <citation>Johnson GK, Geenen JE, Johanson JF, Sherman S, Hogan WJ, Cass O. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1997 Sep;46(3):217-22.</citation>
    <PMID>9378207</PMID>
  </reference>
  <reference>
    <citation>Ohno T, Katori M, Nishiyama K, Saigenji K. Direct observation of microcirculation of the basal region of rat gastric mucosa. J Gastroenterol. 1995 Oct;30(5):557-64.</citation>
    <PMID>8574325</PMID>
  </reference>
  <reference>
    <citation>Xu LH, Qian JB, Gu LG, Qiu JW, Ge ZM, Lu F, Wang YM, Li YM, Lu HS. Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol. 2011 Jul;26(7):1139-44. doi: 10.1111/j.1440-1746.2011.06718.x.</citation>
    <PMID>21392105</PMID>
  </reference>
  <reference>
    <citation>Testoni PA, Mariani A, Aabakken L, Arvanitakis M, Bories E, Costamagna G, Devière J, Dinis-Ribeiro M, Dumonceau JM, Giovannini M, Gyokeres T, Hafner M, Halttunen J, Hassan C, Lopes L, Papanikolaou IS, Tham TC, Tringali A, van Hooft J, Williams EJ. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016 Jul;48(7):657-83. doi: 10.1055/s-0042-108641. Epub 2016 Jun 14.</citation>
    <PMID>27299638</PMID>
  </reference>
  <reference>
    <citation>Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology.. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218. Epub 2013 Jul 30. Erratum in: Am J Gastroenterol. 2014 Feb;109(2):302.</citation>
    <PMID>23896955</PMID>
  </reference>
  <reference>
    <citation>Working Group IAP/APA Acute Pancreatitis Guidelines.. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. doi: 10.1016/j.pan.2013.07.063.</citation>
    <PMID>24054878</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>February 15, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Yanglin Pan</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>ERCP, post-ERCP pancreatitis, indomethacin, epinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
